Bristol-Myers Reports 97% Cure Rate of Hepatitis C in Study of Patients Co-Infected with HIV
Bristol-Myers announced positive results on Tuesday on a phase 3 clinical trial that evaluated the efficacy of once-daily combination of daclatasvir and sofosbuvir to treat chronic hepatitis C in patients co-infected with HIV. The results showed that the treatment was effective on 97% of patients treated for 12 weeks.
“The data showed results that are very promising in patients that are well known as being both difficult to treat and at higher risk for developing serious liver disease, making the results all the more significant,” said Dr. Stephen Shafran , professor of medicine at the University of Alberta . “It’s also important to note that we are seeing high cure rates with the daclatasvir and sofosbuvir combination regardless of the genotype of the hepatitis C infection.”
BMY was up a penny at $62.31 in recent pre-market activity, moving in the upper half of the 52-week range of $46.30 to $64.44.